Susan E. Shoaf

5.1k total citations · 1 hit paper
81 papers, 3.8k citations indexed

About

Susan E. Shoaf is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Susan E. Shoaf has authored 81 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 21 papers in Molecular Biology and 16 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Susan E. Shoaf's work include Electrolyte and hormonal disorders (22 papers), Ion Transport and Channel Regulation (14 papers) and Genetic and Kidney Cyst Diseases (13 papers). Susan E. Shoaf is often cited by papers focused on Electrolyte and hormonal disorders (22 papers), Ion Transport and Channel Regulation (14 papers) and Genetic and Kidney Cyst Diseases (13 papers). Susan E. Shoaf collaborates with scholars based in United States, Germany and Spain. Susan E. Shoaf's co-authors include Mitchell B. Max, Ronald Dubner, Joanne Muir, Sue Lynch, Bruce M Smoller, Suresh Mallikaarjun, M. Linnoila, Patricia Bricmont, Robert R. Rawlings and Ben J. Roberts and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and American Journal of Psychiatry.

In The Last Decade

Susan E. Shoaf

79 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of Desipramine, Amitriptyline, and Fluoxetine on Pain in Diabetic Neuropathy

1992 794 citations Susan E. Shoaf et al. profile →

Peers

Countries citing papers authored by Susan E. Shoaf

Since Specialization

Citations

This map shows the geographic impact of Susan E. Shoaf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan E. Shoaf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan E. Shoaf more than expected).

Fields of papers citing papers by Susan E. Shoaf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan E. Shoaf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan E. Shoaf. The network helps show where Susan E. Shoaf may publish in the future.

Co-authorship network of co-authors of Susan E. Shoaf

This figure shows the co-authorship network connecting the top 25 collaborators of Susan E. Shoaf. A scholar is included among the top collaborators of Susan E. Shoaf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan E. Shoaf. Susan E. Shoaf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Conducting clinical trials with self-collection of pharmacokinetic samples: Experience from an exploratory, phase 1, open-label trial of centanafadine SR in healthy individuals 2024 ·Contemporary Clinical Trials Communications ·(unknown), (unknown), Susan E. Shoaf, (unknown), (unknown)	2
2	At‐Home Self‐Collection of Pharmacokinetic Data: Design and Results From a Phase 1 Open‐Label Feasibility Trial 2024 ·Clinical Pharmacology in Drug Development ·(unknown), Susan E. Shoaf, Brian Rothman, (unknown), (unknown)	1
3	#3034 PHASE 3 TRIAL OF TOLVAPTAN IN PEDIATRIC AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): TWO YEARS OF DATA FROM AN OPEN-LABEL EXTENSION 2023 ·Nephrology Dialysis Transplantation ·Djalila Mekahli, Lisa M. Guay‐Woodford, (unknown), Laurence Greenbaum, Mieczysław Litwin, Tomáš Seeman, (unknown), (unknown), (unknown), Susan E. Shoaf, Franz Schaefer	0
4	Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease 2023 ·Clinical Journal of the American Society of Nephrology ·Djalila Mekahli, Lisa M. Guay‐Woodford, Melissa A. Cadnapaphornchai, Larry A. Greenbaum, Mieczysław Litwin, Tomáš Seeman, (unknown), (unknown), (unknown), Susan E. Shoaf, Franz Schaefer	22
5	Low-dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults 2017 ·European Journal of Clinical Pharmacology ·Susan E. Shoaf, Patricia Bricmont, (unknown)	17
6	Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4 2017 ·Kidney International Reports ·Olivier Devuyst, Arlene B. Chapman, Susan E. Shoaf, Frank S. Czerwiec, Jaime D. Blais	36
7	Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors 2016 ·Toxicological Sciences ·Jeffrey L. Woodhead, William J. Brock, Sharin E. Roth, Susan E. Shoaf, Kim L. R. Brouwer, Rachel J. Church, Tom N. Grammatopoulos, Linsey Stiles, Scott Q. Siler, Brett A. Howell, Merrie Mosedale, Paul B. Watkins, Lisl K.M. Shoda	71
8	Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function 2013 ·Kidney International ·Susan E. Shoaf, Patricia Bricmont, Suresh Mallikaarjun	34
9	Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects 2011 ·European Journal of Clinical Pharmacology ·Susan E. Shoaf, Suresh Mallikaarjun, Patricia Bricmont	20
10	Serotonergic influences on life‐history outcomes in free‐ranging male rhesus macaques 2007 ·American Journal of Primatology ·(unknown), (unknown), (unknown), (unknown), Susan E. Shoaf, Allison Cleveland, Philip Snoy, Stephen J. Suomi, J. Dee Higley	37
11	Pharmacokinetic and Pharmacodynamic Interaction Between Tolvaptan, a Non-Peptide AVP Antagonist, and Furosemide or Hydrochlorothiazide 2007 ·Journal of Cardiovascular Pharmacology ·Susan E. Shoaf, Steven L. Bramer, Patricia Bricmont, Christopher A. Zimmer	46
12	Inverse relationship between plasma epinephrine and testosterone levels during acute glucoprivation in healthy men 2001 ·Life Sciences ·Igor Elman, David S. Goldstein, Caleb M. Adler, Susan E. Shoaf, Alan Breier	24
13	Ondansetron modulates pharmacodynamic effects of ketamine on electrocardiographic signals in rhesus monkeys 2000 ·European Journal of Pharmacology ·Paolo B. DePetrillo, Allyson J. Bennett, (unknown), Stephen J. Suomi, Susan E. Shoaf, (unknown), J. Dee Higley	5
14	Salivary prolactin as a marker for central serotonin turnover 1999 ·Biological Psychiatry ·Stephen G. Lindell, Stephen J. Suomi, Susan E. Shoaf, J. Dee Higley, Markku Linnoila	15
15	Effects of Acute Tryptophan Depletion on Plasma and Cerebrospinal Fluid Tryptophan and 5‐Hydroxyindoleacetic Acid in Normal Volunteers 1999 ·Journal of Neurochemistry ·Wendol Williams, Susan E. Shoaf, D. Hommer, Robert R. Rawlings, M. Linnoila	190
16	The Effect of Dietary Polyunsaturated Fatty Acids and Alcohol on Neurotransmitter Levels in Rat Brain 1998 ·Nutritional Neuroscience ·N. Olsson, Susan E. Shoaf, Norman Salem	16
17	Brain Serotonin Synthesis Rates in Rhesus Monkeys Determined by [11C]α-Methyl-?-Tryptophan and Positron Emission Tomography Compared to CSF 5-Hydroxyindole-3-Acetic Acid Concentrations 1998 ·Neuropsychopharmacology ·Susan E. Shoaf	30
18	A replication study of violent and nonviolent subjects: cerebrospinal fluid metabolites of serotonin and dopamine are predicted by plasma essential fatty acids 1998 ·Biological Psychiatry ·Joseph R. Hibbeln, John C. Umhau, Markku Linnoila, David T. George, Paul Ragan, Susan E. Shoaf, Michael R. Vaughan, Robert R. Rawlings, Norman Salem	92
19	Pharmacokinetics of alpha-methyl-L-tryptophan in rhesus monkeys and calculation of the lumped constant for estimating the rate of serotonin synthesis. 1996 ·Journal of Pharmacology and Experimental Therapeutics ·Susan E. Shoaf, Bernard Schmall	18
20	Pharmacokinetic data in the evaluation of the safety of food and color additives 1992 ·Regulatory Toxicology and Pharmacology ·(unknown), Susan E. Shoaf, James C. Griffiths	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact